An interventional study of Interview with Clinicians and Field Test of UPLYFT with Lymphoma Survivors in Lymphoma and Survivorship, sponsored by Dana-Farber Cancer Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.
Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
This is a two phase pilot study to develop and pilot the UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) program intervention that includes lymphoma survivorship information and acceptance and commitment therapy strategies to alleviate fear of cancer recurrence, reduce distress, and improve quality of life among lymphoma survivors.
Phase 1 will be a two-part development process of the UPLYFT program based on interview feedback from lymphoma and mental health clinicians and then feedback from a six-person group of lymphoma survivors after participation in an UPLYFT program field test. Phase 2 is a randomized pilot study using the UPLFYT program finalized in Phase 1.
Research procedures include:
Baseline Assessments and Questionnaires (lymphoma survivors)
74 people are expected to participate in this study with 14 in Phase 1 and 60 in Phase 2.
The American Society of Hematology is providing funding for the trial.
5,578 studies on the registry are indexed under Lymphoma; 825 are open to participants now.
This study's enrollment of 74 is above the median of 40 across 4,508 interventional studies indexed under Lymphoma.
Browse Lymphoma studies →Dana-Farber Cancer Institute is the lead sponsor of 813 studies on the registry; 124 are open to participants now.
Of its 113 completed or terminated interventional studies of FDA-regulated products, 77 (68%) have results posted.
Counted across the registry records on this site, refreshed daily.
Lymphoma Survivors Phase 1 and 2:
Lymphoma clinicians and mental health clinicians Phase 1:
Exclusion Criteria:
Lymphoma Survivors Phase 1:
Lymphoma Survivors Phase 2:
Patients with uncontrolled/untreated psychotic disorders or untreated bipolar and borderline personality disorders (as ascertained from medical record screen).
Our study will exclude members of the following special populations:
Lymphoma and mental health clinicians will participate in 1x in-depth qualitative interview to provide feedback for the development of the UPLYFT program.
Other: Interview with Clinicians
A six person group of lymphoma survivors will participate in a six session UPLYFT program field test to provide feedback for the development of the UPLYFT program.
Other: Field Test of UPLYFT with Lymphoma Survivors
Lymphoma survivors will participate in the phase 1 finalized, six session UPLYFT program. Participants will be randomized 1:1 to either UPLYFT or usual care.
Behavioral: Pilot of UPLYFT with Lymphoma Survivors
One time, qualitative interview of clinicians for feedback on UPLYFT intervention
6 session of UPLYFT intervention with Lymphoma Survivors for feedback
6 session of UPLYFT intervention with Lymphoma Survivors
Feasibility: Enrollment Rate
Proportion of eligible patients approached that enroll in the study.
Time frame: Up to 6 months
Feasibility: Program Session Completion Rate
Proportion of study participants randomized to the intervention arm (UPLYFT) who complete all intervention sessions.
Time frame: Up to 6 months
Feasibility: Data Collection Completion Rate
Proportion of enrolled participants who complete assigned patient-reported questionnaires during the study.
Time frame: Up to 6 months
Acceptability: Satisfaction Rate
Satisfaction rate is defined as the proportion of study participants randomized to the intervention arm who are satisfied with the UPLYFT program and proportion who are likely to recommend the program.
Time frame: Up to 6 months
Acceptability: Disenrollment Rate
Disenrollment rate is defined as the proportion of eligible patients who enroll in the study who then choose to disenroll from the study.
Time frame: Up to 6 months
Preliminary efficacy: Fear of Cancer Recurrence (FCR) Change
Pre-intervention to post-intervention changes in Fear of Cancer Recurrence (FCR) measured with the Fear of Cancer Recurrence Inventory (FCRI, 42-item questionnaire), with a focus on the FCRI severity subscale.
Time frame: Up to 6 months
Preliminary efficacy: Quality of Life Change
Pre-intervention to post-intervention changes in quality of life measured with the Quality of Life- Cancer Survivor instrument (a 41-item questionnaire)
Time frame: Up to 6 months
Preliminary efficacy: Anxiety Change
Pre-intervention to post-intervention changes in anxiety as measured by the Hospital and Anxiety Scale (Anxiety subscale)
Time frame: Up to 6 months
Preliminary efficacy: Depression Change
Pre-intervention to post-intervention changes in depression as measured by the Hospital Anxiety and Depression Scale (Depression subscale)
Time frame: Up to 6 months
Preliminary efficacy: Psychological inflexibility Change
Pre-intervention to post-intervention changes in psychological inflexibility as measured by the Acceptance and Action Questionnaire-II (a 7-item scale)
Time frame: Up to 6 months
Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Sap, Icf
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dana-Farber Cancer Institute